Cardiovascular Systems Company Profile (NASDAQ:CSII)

About Cardiovascular Systems (NASDAQ:CSII)

Cardiovascular Systems logoCardiovascular Systems, Inc. is a medical technology company. The Company is engaged in treating patients suffering from peripheral and coronary artery diseases, including those with arterial calcium. The Company develops an orbital atherectomy technology for both peripheral and coronary commercial applications. Its peripheral artery disease (PAD) systems are catheter-based platforms capable of treating a range of plaque types in leg arteries both above and below the knee. Its products include Diamondback 360 Peripheral Orbital Atherectomy System (OAS) (Diamondback 360 Peripheral), the Stealth 360 OAS (Stealth 360), Diamondback 360 Peripheral, Diamondback 360 60cm Peripheral, Diamondback 360 Low Profile Peripheral, Diamondback 360 1.50 Peripheral and Diamondback 360 2.00 Peripheral. The Company's coronary arterial disease (CAD) product, Diamondback 360 Coronary OAS (Coronary OAS), is marketed as a treatment for severely calcified coronary arteries.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Equipment, Supplies & Distribution - NEC
  • Sub-Industry: Health Care Equipment
  • Symbol: NASDAQ:CSII
  • CUSIP: 14161910
  • Web:
  • Market Cap: $1.00622 billion
  • Outstanding Shares: 32,712,000
Average Prices:
  • 50 Day Moving Avg: $31.03
  • 200 Day Moving Avg: $27.88
  • 52 Week Range: $16.57 - $32.68
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 758.25
  • P/E Growth: -15.79
Sales & Book Value:
  • Annual Revenue: $199.17 million
  • Price / Sales: 4.98
  • Book Value: $3.47 per share
  • Price / Book: 8.74
  • EBIDTA: ($1,900,000.00)
  • Net Margins: -3.72%
  • Return on Equity: -4.36%
  • Return on Assets: -2.99%
  • Debt-to-Equity Ratio: 0.18%
  • Current Ratio: 3.93%
  • Quick Ratio: 3.50%
  • Average Volume: 318,009 shs.
  • Beta: 2.59
  • Short Ratio: 2.27

Frequently Asked Questions for Cardiovascular Systems (NASDAQ:CSII)

What is Cardiovascular Systems' stock symbol?

Cardiovascular Systems trades on the NASDAQ under the ticker symbol "CSII."

How were Cardiovascular Systems' earnings last quarter?

Cardiovascular Systems, Inc. (NASDAQ:CSII) announced its earnings results on Wednesday, May, 3rd. The company reported ($0.05) EPS for the quarter, hitting the consensus estimate of ($0.05). The company earned $52.10 million during the quarter, compared to analysts' expectations of $51.13 million. Cardiovascular Systems had a negative net margin of 3.72% and a negative return on equity of 4.36%. The business's revenue for the quarter was up 17.1% on a year-over-year basis. During the same period last year, the company posted ($0.31) earnings per share. View Cardiovascular Systems' Earnings History.

When will Cardiovascular Systems make its next earnings announcement?

Cardiovascular Systems is scheduled to release their next quarterly earnings announcement on Tuesday, August, 1st 2017. View Earnings Estimates for Cardiovascular Systems.

What guidance has Cardiovascular Systems issued on next quarter's earnings?

Cardiovascular Systems issued an update on its fourth quarter earnings guidance on Wednesday, May, 3rd. The company provided EPS guidance of ($0.06)-($0.04) for the period, compared to the Thomson Reuters consensus earnings per share estimate of ($0.03). The company issued revenue guidance of $51.5-$52.5 million, compared to the consensus revenue estimate of $53.79 million.

Where is Cardiovascular Systems' stock going? Where will Cardiovascular Systems' stock price be in 2017?

6 equities research analysts have issued 1 year target prices for Cardiovascular Systems' stock. Their forecasts range from $30.00 to $40.00. On average, they expect Cardiovascular Systems' share price to reach $33.40 in the next twelve months. View Analyst Ratings for Cardiovascular Systems.

What are analysts saying about Cardiovascular Systems stock?

Here are some recent quotes from research analysts about Cardiovascular Systems stock:

  • 1. According to Zacks Investment Research, "Cardiovascular Systems posted solid second quarter of fiscal 2017, with both earnings and sales ahead of the respective Zacks Consensus Estimate. We are also encouraged by the company’s improving operating expense scenario, driving year-over-year rise in the earnings figure. Per management, the company delivered improved results over the past four quarters, showing major progress in driving revenue growth, while moving toward positive cash flow and profitability. On the flip side, share price trend over the past one month that traded below the broader Medical Products Industry. The company operates in the competitive medical device industry. Additionally, the company expects to witness net loss in the next third quarter a rise in its general and administrative expenses with growth in its business. All these indicate that there is no near term respite from the continuing operating loss structure." (3/16/2017)
  • 2. Needham & Company LLC analysts commented, "CSII's F2Q17 revenue and EPS beat consensus. However, F3Q17 revenue and EPS guidance was slightly below consensus. CSII continued on its path to profitability with adjusted EBITDA of $4.6M and cash flow of $5.9M (excluding a one-time $10M payment from Medikit). While revenue growth exceeded 20% Y/ Y for the first time in six quarters, we note that F2Q17 marked the bottom for its revenue growth comps. And although CSII's revenue growth may slow as it faces increasingly difficult comps over the next few quarters, we think it can sustain doubledigit revenue growth. We think that F3Q17 guidance is conservative, and we expect additional revenue and EBITDA upside. Reiterate Buy rating." (1/26/2017)

Are investors shorting Cardiovascular Systems?

Cardiovascular Systems saw a increase in short interest in May. As of May 15th, there was short interest totalling 1,278,065 shares, an increase of 3.6% from the April 28th total of 1,233,330 shares. Based on an average trading volume of 657,874 shares, the short-interest ratio is presently 1.9 days.

Who are some of Cardiovascular Systems' key competitors?

Who are Cardiovascular Systems' key executives?

Cardiovascular Systems' management team includes the folowing people:

  • Scott R. Ward, Chairman of the Board, President, Chief Executive Officer
  • Laurence L. Betterley, Chief Financial Officer
  • Kevin J. Kenny, Chief Operating Officer
  • Martha Goldberg Aronson, Independent Director
  • Scott A. Bartos, Independent Director
  • Brent G. Blackey, Independent Director
  • Edward M. Brown, Independent Director
  • William E. Cohn M.D., Independent Director

Who owns Cardiovascular Systems stock?

Cardiovascular Systems' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Wellington Management Group LLP (8.49%), Camber Capital Management LLC (5.35%), Champlain Investment Partners LLC (5.34%), Vanguard Group Inc. (5.07%), Cortina Asset Management LLC (2.64%) and Frontier Capital Management Co. LLC (2.54%). Company insiders that own Cardiovascular Systems stock include Alexander Rosenstein, Brent G Blackey, Camber Capital Management Llc, David Martin, Edward M Brown, Kevin J Kenny, Laura Gillund, Laurence L Betterley, Paul A Koehn, Robert J Thatcher and Scott R Ward. View Institutional Ownership Trends for Cardiovascular Systems.

Who sold Cardiovascular Systems stock? Who is selling Cardiovascular Systems stock?

Cardiovascular Systems' stock was sold by a variety of institutional investors in the last quarter, including Granahan Investment Management Inc. MA, Camber Capital Management LLC, Citadel Advisors LLC, Next Century Growth Investors LLC, JPMorgan Chase & Co., Renaissance Technologies LLC, Driehaus Capital Management LLC and Bogle Investment Management L P DE. Company insiders that have sold Cardiovascular Systems stock in the last year include Alexander Rosenstein, Camber Capital Management Llc, Edward M Brown, Kevin J Kenny, Laura Gillund, Laurence L Betterley and Paul A Koehn. View Insider Buying and Selling for Cardiovascular Systems.

Who bought Cardiovascular Systems stock? Who is buying Cardiovascular Systems stock?

Cardiovascular Systems' stock was purchased by a variety of institutional investors in the last quarter, including Cortina Asset Management LLC, MARSHALL WACE ASIA Ltd, Marshall Wace North America L.P., Vanguard Group Inc., Brown Capital Management LLC, Wellington Management Group LLP, Redwood Investments LLC and Monarch Partners Asset Management LLC. Company insiders that have bought Cardiovascular Systems stock in the last two years include Brent G Blackey, Camber Capital Management Llc and Scott R Ward. View Insider Buying and Selling for Cardiovascular Systems.

How do I buy Cardiovascular Systems stock?

Shares of Cardiovascular Systems can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cardiovascular Systems' stock price today?

One share of Cardiovascular Systems stock can currently be purchased for approximately $30.33.

MarketBeat Community Rating for Cardiovascular Systems (NASDAQ CSII)
Community Ranking:  3.3 out of 5 (  )
Outperform Votes:  181 (Vote Outperform)
Underperform Votes:  95 (Vote Underperform)
Total Votes:  276
MarketBeat's community ratings are surveys of what our community members think about Cardiovascular Systems and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Cardiovascular Systems (NASDAQ:CSII) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 4 Buy Ratings, 1 Strong Buy Rating
Consensus Rating:Buy (Score: 2.83)
Consensus Price Target: $33.40 (10.12% upside)

Analysts' Ratings History for Cardiovascular Systems (NASDAQ:CSII)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
6/21/2017Bank of America CorporationDowngradeNeutral -> UnderperformLowView Rating Details
4/18/2017Needham & Company LLCReiterated RatingBuy$32.00LowView Rating Details
1/30/2017Lake Street CapitalInitiated CoverageBuy$40.00N/AView Rating Details
11/15/2016Leerink SwannReiterated RatingOutperform$30.00N/AView Rating Details
10/27/2016Feltl & Co.UpgradeBuy -> Strong-Buy$30.00N/AView Rating Details
10/7/2016JMP SecuritiesInitiated CoverageOutperform$35.00N/AView Rating Details
12/23/2015Northcoast ResearchInitiated CoverageBuy$18.00N/AView Rating Details
10/8/2015William BlairReiterated RatingOutperformN/AView Rating Details
10/8/2015Dougherty & CoLower Price TargetBuy$50.00 -> $32.00N/AView Rating Details
10/8/2015Benchmark Co.Lower Price TargetBuy$49.00 -> $20.00N/AView Rating Details
(Data available from 6/28/2015 forward)


Earnings History for Cardiovascular Systems (NASDAQ:CSII)
Earnings by Quarter for Cardiovascular Systems (NASDAQ:CSII)
Earnings History by Quarter for Cardiovascular Systems (NASDAQ CSII)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/3/2017Q3 2017($0.05)($0.05)$51.13 million$52.10 millionViewListenView Earnings Details
1/25/2017Q217($0.06)$0.03$49.72 million$50.00 millionViewN/AView Earnings Details
10/26/2016Q117($0.18)($0.06)$205.50 million$49.80 millionViewListenView Earnings Details
8/3/2016Q416($0.20)($0.15)$46.01 million$48.50 millionViewN/AView Earnings Details
5/4/2016Q316($0.54)($0.31)$42.13 million$44.50 millionViewN/AView Earnings Details
1/21/2016Q216($0.50)($0.47)$44.82 million$41.40 millionViewListenView Earnings Details
11/4/2015Q116($0.42)($0.41)$43.90 million$43.90 millionViewN/AView Earnings Details
8/5/2015Q415($0.30)($0.27)$50.10 million$48.50 millionViewN/AView Earnings Details
4/29/2015Q315($0.33)($0.34)$46.84 million$47.00 millionViewListenView Earnings Details
1/28/2015Q215($0.34)($0.17)$43.97 million$44.70 millionViewListenView Earnings Details
10/29/2014Q115($0.33)($0.26)$40.24 million$41.40 millionViewListenView Earnings Details
8/6/2014Q214($0.28)($0.31)$37.21 million$39.56 millionViewListenView Earnings Details
4/30/2014Q114($0.32)($0.32)$34.15 million$34.90 millionViewListenView Earnings Details
1/29/2014Q2($0.34)($0.32)$30.62 million$32.30 millionViewListenView Earnings Details
8/7/2013Q4 2013($0.30)($0.28)$27.18 million$28.80 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Cardiovascular Systems (NASDAQ:CSII)
2017 EPS Consensus Estimate: ($0.45)
2018 EPS Consensus Estimate: $0.14
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20174($0.44)($0.14)($0.26)
Q2 20174($0.26)($0.05)($0.11)
Q3 20174($0.05)($0.02)($0.04)
Q4 20174($0.06)($0.02)($0.04)
Q1 20184($0.01)$0.02$0.00
Q2 20184$0.01$0.03$0.02
Q3 20183$0.03$0.05$0.04
Q4 20184$0.03$0.09$0.07
(Data provided by Zacks Investment Research)


Dividend History for Cardiovascular Systems (NASDAQ:CSII)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Cardiovascular Systems (NASDAQ:CSII)
Insider Ownership Percentage: 3.60%
Institutional Ownership Percentage: 75.85%
Insider Trades by Quarter for Cardiovascular Systems (NASDAQ:CSII)
Institutional Ownership by Quarter for Cardiovascular Systems (NASDAQ:CSII)
Insider Trades by Quarter for Cardiovascular Systems (NASDAQ:CSII)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/17/2017Alexander RosensteinGeneral CounselSell219$32.30$7,073.70View SEC Filing  
11/18/2016Alexander RosensteinGeneral CounselSell529$26.80$14,177.20View SEC Filing  
11/18/2016Edward M BrownDirectorSell10,000$26.78$267,800.00View SEC Filing  
11/18/2016Laura GillundInsiderSell1,268$26.79$33,969.72View SEC Filing  
11/15/2016Edward M BrownDirectorSell10,000$24.95$249,500.00View SEC Filing  
10/10/2016Paul A KoehnSVPSell30,910$25.07$774,913.70View SEC Filing  
9/20/2016Camber Capital Management LlcMajor ShareholderSell1,100,000$23.26$25,586,000.00View SEC Filing  
9/7/2016Paul A KoehnSVPSell5,969$25.02$149,344.38View SEC Filing  
8/22/2016Alexander RosensteinGeneral CounselSell234$23.82$5,573.88View SEC Filing  
8/22/2016Kevin J KennyCOOSell3,166$23.95$75,825.70View SEC Filing  
8/22/2016Laura GillundInsiderSell1,395$23.93$33,382.35View SEC Filing  
8/22/2016Laurence L BetterleyCFOSell3,568$23.96$85,489.28View SEC Filing  
8/22/2016Paul A KoehnSVPSell2,527$23.92$60,445.84View SEC Filing  
8/17/2016Paul A KoehnSVPSell4,000$22.17$88,680.00View SEC Filing  
2/26/2016Paul A KoehnSVPSell956$38.79$37,083.24View SEC Filing  
2/23/2016Camber Capital Management LlcMajor ShareholderBuy250,000$7.55$1,887,500.00View SEC Filing  
1/25/2016Scott R WardCEOBuy2,700$9.30$25,110.00View SEC Filing  
10/2/2015Robert J. ThatcherinsiderSell64,700$16.31$1,055,257.00View SEC Filing  
9/2/2015David MartinCEOSell19,646$23.81$467,771.26View SEC Filing  
9/1/2015Kevin J KennyCOOSell5,289$23.85$126,142.65View SEC Filing  
9/1/2015Laurence L BetterleyCFOSell9,597$23.96$229,944.12View SEC Filing  
9/1/2015Paul A KoehnSVPSell4,946$23.86$118,011.56View SEC Filing  
9/1/2015Robert J ThatcherInsiderSell5,282$23.85$125,975.70View SEC Filing  
8/18/2015David MartinCEOSell17,688$23.99$424,335.12View SEC Filing  
8/18/2015Kevin J. KennyCOOSell3,913$24.00$93,912.00View SEC Filing  
8/18/2015Laurence L BetterleyCFOSell8,476$24.00$203,424.00View SEC Filing  
8/18/2015Paul A. KoehnSVPSell4,402$23.99$105,603.98View SEC Filing  
8/18/2015Robert J. ThatcherinsiderSell2,960$23.99$71,010.40View SEC Filing  
8/12/2015Brent G BlackeyDirectorBuy2,500$22.74$56,850.00View SEC Filing  
5/28/2015Paul A KoehnSVPSell4,389$27.86$122,277.54View SEC Filing  
5/1/2015Brent G BlackeyDirectorBuy2,500$29.38$73,450.00View SEC Filing  
2/10/2015David MartinCEOSell7,500$35.85$268,875.00View SEC Filing  
2/5/2015David MartinCEOSell4,500$34.96$157,320.00View SEC Filing  
1/29/2015Kevin J KennyVPSell4,212$35.00$147,420.00View SEC Filing  
9/3/2014David MartinCEOSell10,248$28.85$295,654.80View SEC Filing  
9/3/2014Kevin J KennyVPSell3,528$28.85$101,782.80View SEC Filing  
9/3/2014Laurence L BetterleyCFOSell4,674$28.82$134,704.68View SEC Filing  
9/3/2014Paul A KoehnSVPSell2,612$28.85$75,356.20View SEC Filing  
9/3/2014Robert J ThatcherInsiderSell2,791$28.85$80,520.35View SEC Filing  
8/28/2014Paul A KoehnSVPSell1,315$28.82$37,898.30View SEC Filing  
8/22/2014David MartinCEOSell13,957$29.03$405,171.71View SEC Filing  
8/22/2014Kevin J KennyVPSell2,914$29.09$84,768.26View SEC Filing  
8/22/2014Laurence L BetterleyCFOSell6,578$29.02$190,893.56View SEC Filing  
8/22/2014Paul A KoehnSVPSell2,755$29.06$80,060.30View SEC Filing  
8/22/2014Robert J ThatcherInsiderSell3,225$29.06$93,718.50View SEC Filing  
8/19/2014David MartinCEOSell11,754$29.28$344,157.12View SEC Filing  
8/19/2014Kevin J KennyVPSell2,117$29.28$61,985.76View SEC Filing  
8/19/2014Laurence L BetterleyCFOSell5,725$29.28$167,628.00View SEC Filing  
8/19/2014Paul A KoehnSVPSell2,168$29.28$63,479.04View SEC Filing  
8/19/2014Robert J ThatcherInsiderSell2,537$29.28$74,283.36View SEC Filing  
7/16/2014David MartinCEOSell10,703$28.83$308,567.49View SEC Filing  
7/16/2014Kevin J KennyVPSell3,007$28.83$86,691.81View SEC Filing  
7/16/2014Laurence L BetterleyCFOSell3,984$28.83$114,858.72View SEC Filing  
7/16/2014Paul A KoehnSVPSell2,716$28.83$78,302.28View SEC Filing  
7/16/2014Robert J ThatcherInsiderSell2,939$28.83$84,731.37View SEC Filing  
4/25/2014Kevin KennyVPSell15,484$28.79$445,784.36View SEC Filing  
2/24/2014David MartinCEOSell29,200$37.31$1,089,452.00View SEC Filing  
2/20/2014Kevin KennyVPSell6,779$36.02$244,179.58View SEC Filing  
1/30/2014David MartinCEOSell50,000$35.12$1,756,000.00View SEC Filing  
1/30/2014Robert ThatcherVPSell35,139$35.06$1,231,973.34View SEC Filing  
11/22/2013Robert ThatcherVPSell22,384$32.82$734,642.88View SEC Filing  
10/31/2013James E FlahertyInsiderSell34,819$30.35$1,056,756.65View SEC Filing  
10/23/2013David MartinCEOSell154,080$27.73$4,272,638.40View SEC Filing  
10/23/2013James E FlahertyInsiderSell36,682$26.85$984,911.70View SEC Filing  
10/23/2013Robert J ThatcherVPSell23,426$28.19$660,378.94View SEC Filing  
10/22/2013Kevin J KennyVPSell5,608$27.31$153,154.48View SEC Filing  
10/16/2013Kevin J KennyVPSell4,182$22.95$95,976.90View SEC Filing  
10/14/2013David MartinCEOSell21,170$22.00$465,740.00View SEC Filing  
9/20/2013David MartinCEOSell6,702$20.24$135,648.48View SEC Filing  
9/20/2013James FlahertyInsiderSell2,066$20.28$41,898.48View SEC Filing  
9/20/2013Robert ThatcherVPSell1,274$20.28$25,836.72View SEC Filing  
9/19/2013Laurence BetterleyCFOSell2,694$20.32$54,742.08View SEC Filing  
9/19/2013Paul KoehnSVPSell1,094$20.32$22,230.08View SEC Filing  
9/18/2013David MartinCEOSell8,030$20.94$168,148.20View SEC Filing  
9/18/2013James FlahertyInsiderSell2,970$20.94$62,191.80View SEC Filing  
9/18/2013Laurence BetterleyCFOSell4,324$20.93$90,501.32View SEC Filing  
9/18/2013Paul KoehnSVPSell1,732$20.93$36,250.76View SEC Filing  
9/18/2013Robert ThatcherVPSell1,731$20.94$36,247.14View SEC Filing  
9/10/2013John FriedmanDirectorSell48,273$20.73$1,000,699.29View SEC Filing  
8/30/2013David MartinCEOSell21,552$20.64$444,833.28View SEC Filing  
8/30/2013James FlahertyInsiderSell7,165$20.64$147,885.60View SEC Filing  
8/30/2013Kevin KennyVPSell1,899$20.64$39,195.36View SEC Filing  
8/30/2013Laurence BetterleyCFOSell8,692$20.64$179,402.88View SEC Filing  
8/27/2013David MartinCEOSell27,229$21.07$573,715.03View SEC Filing  
8/27/2013James FlahertyInsiderSell9,051$21.07$190,704.57View SEC Filing  
8/27/2013Kevin KennyVPSell2,396$21.07$50,483.72View SEC Filing  
8/27/2013Laurence BetterleyCFOSell10,982$21.07$231,390.74View SEC Filing  
8/16/2013James FlahertyInsiderSell1,255$20.51$25,740.05View SEC Filing  
8/16/2013Laurence BetterleyCFOSell1,568$20.51$32,159.68View SEC Filing  
8/14/2013James FlahertyInsiderSell4,902$21.31$104,461.62View SEC Filing  
8/13/2013Kevin KennyVPSell2,529$21.20$53,614.80View SEC Filing  
8/8/2013James FlahertyInsiderSell19,649$22.27$437,583.23View SEC Filing  
7/30/2013David MartinCEOSell11,094$19.69$218,440.86View SEC Filing  
7/30/2013Laurence L BetterleyCFOSell6,579$19.72$129,737.88View SEC Filing  
7/30/2013Robert J ThatcherVPSell3,112$19.86$61,804.32View SEC Filing  
6/3/2013James E FlahertyInsiderSell10,000$21.00$210,000.00View SEC Filing  
5/31/2013Paul A KoehnVPSell2,472$20.00$49,440.00View SEC Filing  
5/28/2013Kevin J KennyVPSell4,182$19.95$83,430.90View SEC Filing  
5/20/2013Glen D NelsonDirectorBuy10,250$18.47$189,317.50View SEC Filing  
5/16/2013Glen D NelsonDirectorBuy4,753$18.93$89,974.29View SEC Filing  
5/13/2013Glen D NelsonDirectorBuy18,393$18.11$333,097.23View SEC Filing  
11/13/2012Glen D NelsonDirectorBuy33,000$11.96$394,680.00View SEC Filing  
8/23/2012David MartinCEOSell10,510$9.07$95,325.70View SEC Filing  
8/23/2012James E FlahertyInsiderSell4,018$9.07$36,443.26View SEC Filing  
8/23/2012Laurence L BetterleyCFOSell4,770$9.07$43,263.90View SEC Filing  
8/23/2012Paul A KoehnVPSell2,496$9.07$22,638.72View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Cardiovascular Systems (NASDAQ:CSII)
Latest Headlines for Cardiovascular Systems (NASDAQ:CSII)
DateHeadline logoETFs with exposure to Cardiovascular Systems, Inc. : June 26, 2017 - June 26 at 5:19 PM logoCardiovascular Systems (CSII) Presents At JMP Securities Life Sciences Conference - Slideshow - June 22 at 9:53 PM logoCardiovascular Systems, Inc. (CSII) Stock Rating Lowered by Bank of America Corporation - June 21 at 11:20 AM logoCardiovascular Systems, Inc. (CSII) Given Average Rating of "Buy" by Brokerages - June 19 at 8:00 AM logoETFs with exposure to Cardiovascular Systems, Inc. : June 16, 2017 - June 16 at 5:17 PM logoCardiovascular Systems, Inc. :CSII-US: Earnings Analysis: Q3, 2017 By the Numbers : June 14, 2017 - June 14 at 5:28 PM logoCardiovascular Systems to Present at the JMP Securities Life Sciences Conference - June 14 at 5:28 PM logoCardiovascular Systems Inc (CSII) Upgraded at BidaskClub - June 10 at 9:20 AM logo$52.04 Million in Sales Expected for Cardiovascular Systems Inc (CSII) This Quarter - June 10 at 7:34 AM logoAdherium Appoints New CEO to Drive Global Growth - June 9 at 10:58 AM logoZacks: Brokerages Expect Cardiovascular Systems Inc (CSII) Will Announce Earnings of -$0.05 Per Share - June 9 at 12:08 AM logoCommit To Purchase Cardiovascular Systems At $25, Earn 9.2% Annualized Using Options - June 8 at 10:33 PM logoCardiovascular Systems (CSII) Up 2.3% Since Earnings Report: Can It Continue? - June 6 at 4:46 PM logoCardiovascular Systems Inc (CSII) Short Interest Up 3.6% in May - May 29 at 12:38 PM logoCardiovascular Systems Inc (CSII) Receives Average Recommendation of "Buy" from Analysts - May 23 at 7:30 AM logo-$0.05 Earnings Per Share Expected for Cardiovascular Systems Inc (CSII) This Quarter - May 12 at 8:28 PM logoCardiovascular Systems Inc (CSII) to Post FY2017 Earnings of ($0.12) Per Share, Northcoast Research Forecasts - May 8 at 10:24 AM logoFY2017 EPS Estimates for Cardiovascular Systems Inc Cut by Analyst (CSII) - May 8 at 10:24 AM logoCardiovascular Systems Inc (CSII) Upgraded at TheStreet - May 8 at 12:28 AM logoLeerink Swann Research Analysts Lift Earnings Estimates for Cardiovascular Systems Inc (CSII) - May 5 at 6:08 PM logoQ1 2018 EPS Estimates for Cardiovascular Systems Inc Decreased by Analyst (CSII) - May 5 at 5:24 PM logoCardiovascular Systems Inc (CSII) Announces Quarterly Earnings Results, Meets Estimates - May 4 at 11:10 PM logoInvestor Network: Cardiovascular Systems, Inc. to Host Earnings Call - May 4 at 4:41 PM logoCardiovascular Systems (CSII) Swings to Earnings in Q3 - May 4 at 4:41 PM logoFDA Approves Cardiovascular Systems’ Replacement Saline Infusion Pump - May 4 at 4:41 PM logoCardiovascular Systems' (CSII) CEO Scott Ward on Q3 2017 Results - Earnings Call Transcript - May 4 at 6:59 AM logoEdited Transcript of CSII earnings conference call or presentation 3-May-17 8:45pm GMT - May 4 at 6:59 AM logoCardiovascular Systems Inc (CSII) Given Average Recommendation of "Buy" by Brokerages - May 4 at 1:33 AM logoCardiovascular Systems Inc (CSII) Issues Q4 Earnings Guidance - May 4 at 1:13 AM logoCardiovascular Systems (CSII) Receives Media Impact Rating of 0.30 - May 4 at 1:09 AM logoCardiovascular Systems Inc (CSII) Releases Q4 Earnings Guidance - May 3 at 11:04 PM logoCardiovascular Systems reports 3Q loss - May 3 at 6:05 PM logoCardiovascular Systems, Inc. Reports Fiscal 2017 Third-Quarter Financial Results - May 3 at 4:29 PM logoSomewhat Critical Media Coverage Extremely Likely to Affect Cardiovascular Systems (CSII) Share Price - April 30 at 11:39 AM logoCardiovascular Systems (CSII) Earning Somewhat Critical Press Coverage, Report Finds - April 27 at 5:44 PM logoJury verdict to cost Cardiovascular Systems $25 million - April 27 at 2:09 AM logoCardiovascular Systems Inc (CSII) Receives Buy Rating from Needham & Company LLC - April 24 at 1:13 PM logoCardiovascular Systems (CSII) Given Daily News Impact Rating of 0.56 - April 24 at 1:05 PM logoCardiovascular Systems Inc (CSII) Expected to Post Earnings of -$0.04 Per Share - April 24 at 12:06 PM logoSomewhat Favorable Press Coverage Unlikely to Affect Cardiovascular Systems (CSII) Share Price - April 20 at 8:59 PM logoThousands in Nashville May Be Affected by Peripheral Artery Disease (PAD) - April 19 at 12:41 PM logoThousands in Philadelphia May Be Affected by Peripheral Artery Disease (PAD) - April 19 at 12:41 PM logoThousands in Dallas May Be Affected by Peripheral Artery Disease (PAD) - April 19 at 12:41 PM logoThousands in Phoenix May Be Affected by Peripheral Artery Disease (PAD) - April 19 at 12:41 PM logoCardiovascular Systems (CSII) to Voluntary Recall Saline Infusion Pump - April 18 at 4:19 PM logoCardiovascular Systems' (CSII) "Buy" Rating Reaffirmed at Needham & Company LLC - April 18 at 2:04 PM logoCardiovascular Systems Initiates Voluntary Recall of Saline Infusion Pump - April 18 at 12:13 PM logoCardiovascular Systems Voluntarily Recalls 900 Pumps - April 18 at 12:13 PM logoCardiovascular Systems (CSII) Getting Somewhat Favorable Media Coverage, Report Shows - April 17 at 7:51 PM logoCardiovascular Systems to Webcast Fiscal 2017 Third-Quarter Earnings Conference Call Wednesday, May 3 - Business Wire (press release) - April 7 at 9:14 AM



Cardiovascular Systems (CSII) Chart for Wednesday, June, 28, 2017

This page was last updated on 6/28/2017 by Staff